Revelation Biosciences, Inc. - Equity Warrant
US ˙ NasdaqCM ˙ US76135L1199

Introduction

This page provides a comprehensive analysis of the known insider trading history of James Rolke. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate James Rolke has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:REVB / Revelation Biosciences, Inc. Chief Executive Officer, Director 30,137
US:LJPC / La Jolla Pharmaceutical Co. Chief Scientific Officer 205
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James Rolke. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases REVBW / Revelation Biosciences, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in REVBW / Revelation Biosciences, Inc. - Equity Warrant. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

REVBW / Revelation Biosciences, Inc. - Equity Warrant Insider Trades
Insider Sales REVBW / Revelation Biosciences, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in REVBW / Revelation Biosciences, Inc. - Equity Warrant. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

REVBW / Revelation Biosciences, Inc. - Equity Warrant Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by James Rolke as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-02-13 2025-02-11 4 REVB REVELATION BIOSCIENCES, INC.
Common Stock
A - Award 30,095 30,137 71,654.76 3.87 116,468 116,630
2022-01-20 3 REVB REVELATION BIOSCIENCES, INC.
Common Stock
681,302
2022-01-20 3 REVB REVELATION BIOSCIENCES, INC.
Common Stock
2,144
2020-06-02 2020-05-29 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 205 205
2020-06-02 2020-05-29 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 205 81,771 0.25 4.01 822 327,902
2020-05-19 2020-05-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 140 140
2020-05-19 2020-05-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 140 81,566 0.17 5.86 820 477,977
2020-05-04 2020-04-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 133 133
2020-05-04 2020-04-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 133 81,426 0.16 6.17 821 502,398
2020-04-17 2020-04-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 146 146
2020-04-17 2020-04-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 146 81,293 0.18 5.61 819 456,054
2020-04-02 2020-03-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 229 229
2020-04-02 2020-03-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 229 81,147 0.28 3.57 818 289,695
2020-03-16 2020-03-13 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 241 241
2020-03-16 2020-03-13 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 241 80,918 0.30 3.40 819 275,121
2020-03-03 2020-02-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 142 142
2020-03-03 2020-02-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 142 80,677 0.18 5.78 821 466,313
2020-02-19 2020-02-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 115 115
2020-02-19 2020-02-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 115 80,535 0.14 7.14 821 575,020
2020-02-04 2020-01-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 141 141
2020-02-04 2020-01-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 141 80,420 0.18 5.82 821 468,044
2020-01-17 2020-01-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 692 692
2020-01-17 2020-01-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 692 80,279 0.87 6.70 4,636 537,869
2020-01-13 2020-01-09 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 30,000 30,000
2019-11-19 2019-11-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 118 118
2019-11-19 2019-11-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 118 79,587 0.15 5.12 604 407,485
2019-11-05 2019-10-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 133 133
2019-11-05 2019-10-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 133 79,469 0.17 5.96 793 473,635
2019-10-17 2019-10-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 112 112
2019-10-17 2019-10-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 112 79,336 0.14 7.12 797 564,872
2019-10-02 2019-09-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 107 107
2019-10-02 2019-09-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 107 79,224 0.14 7.48 800 592,596
2019-09-16 2019-09-13 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 85 85
2019-09-16 2019-09-13 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 85 79,117 0.11 9.28 789 734,206
2019-09-03 2019-08-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 98 98
2019-09-03 2019-08-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 98 79,032 0.12 8.13 797 642,530
2019-08-16 2019-08-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 99 99
2019-08-16 2019-08-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 99 78,934 0.13 8.02 794 633,051
2019-08-02 2019-07-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 112 112
2019-08-02 2019-07-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 112 78,835 0.14 7.11 796 560,517
2019-07-17 2019-07-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 102 102
2019-07-17 2019-07-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 102 78,723 0.13 7.85 801 617,976
2019-07-01 2019-06-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 101 101
2019-07-01 2019-06-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 101 78,621 0.13 7.86 794 617,961
2019-06-18 2019-06-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 96 96
2019-06-18 2019-06-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 96 78,520 0.12 8.25 792 647,790
2019-06-03 2019-05-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 174 174
2019-06-03 2019-05-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 174 78,424 0.22 4.58 797 359,182
2019-05-17 2019-05-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 143 143
2019-05-17 2019-05-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 143 78,250 0.18 5.58 798 436,635
2019-05-02 2019-04-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 116 116
2019-05-02 2019-04-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 116 78,107 0.15 6.84 793 534,252
2019-04-17 2019-04-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 131 131
2019-04-17 2019-04-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 131 77,991 0.17 6.09 798 474,965
2019-04-02 2019-03-29 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 146 146
2019-04-02 2019-03-29 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 146 77,860 0.19 5.47 799 425,894
2019-03-19 2019-03-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 122 122
2019-03-19 2019-03-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 122 77,714 0.16 6.49 792 504,364
2019-03-04 2019-02-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 164 164
2019-03-04 2019-02-28 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 164 77,592 0.21 4.85 795 376,321
2019-02-19 2019-02-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 151 151
2019-02-19 2019-02-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 151 77,428 0.20 5.30 800 410,368
2019-02-04 2019-01-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 155 155
2019-02-04 2019-01-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 155 77,277 0.20 5.13 795 396,431
2019-01-25 2019-01-23 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 53,000 53,000
2019-01-17 2019-01-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 792 792
2019-01-17 2019-01-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 792 77,122 1.04 5.74 4,546 442,680
2019-01-09 2019-01-09 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
P - Purchase 800 76,330 1.06 6.10 4,880 465,613
2019-01-09 2019-01-09 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
P - Purchase 500 75,530 0.67 6.09 3,045 459,978
2019-01-09 2019-01-09 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
P - Purchase 300 75,030 0.40 6.07 1,821 455,432
2019-01-03 2018-12-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 97 97
2019-01-03 2018-12-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 97 74,730 0.13 8.02 778 598,998
2018-12-17 2018-12-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 70 70
2018-12-17 2018-12-14 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 70 74,633 0.09 10.88 762 812,007
2018-12-03 2018-11-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 63 63
2018-12-03 2018-11-30 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 63 74,563 0.08 12.30 775 917,088
2018-11-19 2018-11-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 61 61
2018-11-19 2018-11-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 61 74,500 0.08 12.66 773 943,542
2018-11-01 2018-10-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 56 56
2018-11-01 2018-10-31 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 56 74,439 0.08 13.86 776 1,031,352
2018-10-15 2018-10-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 55 55
2018-10-15 2018-10-15 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
A - Award 55 74,383 0.07 13.81 760 1,027,229
2018-08-20 2018-08-16 4 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
P - Purchase 1,000 74,328 1.36 22.00 21,997 1,634,993
2017-12-29 2017-12-27 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 6,700 6,700
2017-12-13 2017-12-11 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 49,000 49,000
2017-01-06 2017-01-04 4 LJPC LA JOLLA PHARMACEUTICAL CO
Stock Option (Right to Buy)
A - Award 64,100 64,100
2017-01-06 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
146,656
2017-01-06 3 LJPC LA JOLLA PHARMACEUTICAL CO
Common Stock
146,656
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)